Healthcare technology company Tabula Rasa HealthCare, Inc. (TRHC) announced Oct. 18 it has signed a letter of intent with the Pharmaceutical Association of Israel (PAI) to promote MedWise Science.
In a statement, TRHC said MedWise Science is in place to help pharmacists assess risks involving medication regimens, pharmacogenomics, pharmacokinetics and pharmacodynamics. The letter of intent is designed to promote MedWise Science among pharmacists in the community, as well as, hospitals and schools located in Israel and the Palestinian Authority.
"We at the Pharmaceutical Association of Israel sincerely believe that the use of innovative technologies in pharmacy operating settings, both community and otherwise, will positively help ensure a better pharmaceutical service for the patient," said David Papo RPh, Chairman, Pharmaceutical Association of Israel. "The potential of the Tabula Rasa systems looks interesting and most promising in this respect.”
The release explains that a personalized MedWise Risk Score is created and then certified MedWise pharmacists recommend ways to reduce the score while improving health and reducing costs.
According to the TRHC website, the MedWise Risk Score began in 2017 and is described as an easy way to assess patients and decide who requires the most immediate medication attention. The score is formulated using data involving a patent’s medication profile.
In the release, TRHC Chairman and CEO Calvin H. Knowlton, Ph.D., called it an “exciting first step” that would help advance the safe use of medication in the region. Knowlton said that MedWise Science will allow Israeli pharmacists to identify patients who are at risk for what he called “adverse drug events.” These events, he said, cause millions of hospitalizations or deaths each year.